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Abstract
Objective: To characterize ocular motor function in patients with Niemann- Pick disease 
type C (NPC).
Methods: In a multicontinental, cross- sectional study we characterized ocular- motor 
function in 72 patients from 12 countries by video- oculography. Interlinking with disease 
severity, we also searched for ocular motor biomarkers. Our study protocol comprised 
reflexive and self- paced saccades, smooth pursuit, and gaze- holding in horizontal and 
vertical planes. Data were compared with those of 158 healthy controls (HC).
Results: Some 98.2% of patients generated vertical saccades below the 95% CI of the 
controls’ peak velocity. Only 46.9% of patients had smooth pursuit gain lower than that 
of 95% CI of HC. The involvement in both downward and upward directions was similar 
(51°/s (68.9, [32.7– 69.3]) downward versus 78.8°/s (65.9, [60.8– 96.8]) upward). Horizontal 
saccadic peak velocity and latency, vertical saccadic duration and amplitude, and horizon-
tal position smooth pursuit correlated best to disease severity. Compensating strategies 
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INTRODUC TION
Eye movement abnormalities are sensitive markers in neurodegen-
erative disorders. One such rare autosomal recessive inborn error 
of metabolism is Niemann- Pick disease type C (NPC), caused by 
a mutation in the NPC1 (95%) or NPC2 genes. Defects result in a 
cellular accumulation of endocytosed unesterified cholesterol and 
glyco- and sphingolipids in the late endosome/lysosome [1]. NPC is 
characterized by heterogenous manifestations that comprise vis-
ceral, neurological, and psychiatric signs. Symptoms are diverse, 
arise at different ages, and progress at various rates [2].
Previously, vertical supranuclear gaze palsy (VSGP), but not 
vertical supranuclear saccade palsy (VSSP), was highlighted as the 
hallmark symptom of NPC at all disease stages [3,4], although the 
predominant vertical saccadic impairment was described in sev-
eral case studies [5– 7]. VSSP is caused by the impairment of burst 
neurons (or their downstream/upstream connections) in the rostral 
interstitial nucleus of the medial longitudinal fascicle (riMLF) in the 
mesencephalon [8]. The burst neurons in the riMLF play a key role 
in the generation of vertical saccades and vertical quick phases of 
nystagmus. VSGP denotes a combined dysfunction of both sac-
cades and smooth pursuit caused by an impairment of the intersti-
tial nucleus of Cajal (InC) in the rostral midbrain and its connections 
through the posterior commissure [9,10].
For the approval of miglustat in treatment of NPC, horizontal 
saccadic dysfunction was used as a surrogate marker [11]. Until now, 
only single cases or small cohorts of NPC patients were thoroughly 
examined for saccadic function [3– 6,12]. Little is known about the 
non- saccadic ocular motor systems, such as smooth pursuit and gaze 
holding, and how any deficits relate to disease severity. In contrast 
to saccadic ocular- motor deficits, vestibulo- ocular reflex of the hor-
izontal semicircular canal and the otoliths are intact in patients with 
NPC [13]. Degeneration in NPC is not restricted to the ocular- motor 
system, but also affects retinal axonal function [14].
This cross- sectional prospective study in a large international 
cohort of patients with NPC had the following objectives. First, 
characterize ocular motor function. Reflexive and self- paced sac-
cades, smooth pursuit, and gaze holding, both vertically and hori-
zontally, were examined.
Second, clarify whether VSSP or VSGP is the hallmark of NPC 
disease, as not all clinicians routinely test for saccadic function in 
ocular- motor examinations and conventional clinical assessment 
of gaze range uses smooth pursuit. Third, correlate ocular- motor 




Of 82 patients screened, 72 patients with genetically and/or bio-
chemically confirmed NPC disease (30 female, 42 male, age ± SD 
28.7 ± 14.2 years, mean disease duration 13.2 ± 9.0 years, mean 
age at the establishment of the diagnosis 22.2 ± 15.3 years) were 
included. Patients who clearly were the most severely impaired, 
practically doing no activity by themselves (patients bound to 
wheelchair, not speaking, with feeding tube, and severe dementia), 
were not screened. These patients were originally (not referring to 
study sites) from Germany (32.46%), Slovakia (1.44%/2 patients), 
Czech Republic (15.3%), Greece (2.8%), Italy (5.6%), Bulgaria 
(0.72%/1 patient), Saudi Arabia (0.72%/1 patient), Spain (18%), 
Sweden (0.72%/1 patient), Turkey (1.44%/2 siblings), Iran (12.5%), 
and Australia (8.3%). The characteristics of all patients are listed 
in Table S1. The mean age at first symptoms of the disease was 
14.7 years (SD ± 95% CI 11.1, [12.1– 17.3]). The first neurological 
symptoms appeared at the age of 16.6 years (12.9, [13.5– 19.7]) and 
the first psychiatric symptoms appeared at the age of 19.0 years 
(10.4, [14.9– 23.1]).
Some 68 of the 72 included patients had a mutations in NPC1, 
and one patient had an additional mutation in NPC2 gene p.E20*. 
The highly frequent mutations p.I1061T and p.P1007A were 
such as blinks to elicit saccades, and head and upper body movements to overcome the 
gaze palsy, were observed. Vertical reflexive saccades were more impaired and slower 
than self- paced ones. Gaze- holding was normal. Ocular- motor performance depended on 
the age of onset and disease duration.
Conclusions: This is the largest cohort of NPC patients investigated for ocular- motor 
function. Vertical supranuclear saccade palsy is the hallmark of NPC. Vertical upward and 
downward saccades are equally impaired. Horizontal saccadic peak velocity and latency, 
vertical saccadic duration and amplitude, and horizontal position smooth pursuit can be 
used as surrogate parameters for clinical trials. Compensating strategies can contribute 
to establishing a diagnosis.
K E Y W O R D S
biomarkers, Niemann- Pick type C, ocular motor function, saccades, supranuclear vertical gaze 
palsy, supranuclear vertical saccade palsy, video- oculography
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present in one patient (p.I1061T). Filipin staining was performed in 
64.6% of all patients: it was variant in 20% and classical in 30.8%. 
In addition, to establish the diagnosis and disease development, 
elevated levels of lysosphingolipids were detected in 9 (9.7%), ox-
ysterols in 17 (23.6%) and, most commonly, chitotriosidase in 25 
patients (34.7%). Most patients were on medication with miglustat 
(62 patients, 86.1%). The mean duration (±SD, 95% CI) of miglustat 
treatment was 3.9 years (3.1, [2.9– 5.0]). Twenty- eight patients 
(68.3%) were on miglustat for longer than 1 year and 13 (31.7%) 
for less than 1 year.
Regarding the NPC form, 2 patients (3.2%) were early- infantile, 
5 (7.8%) late- infantile, 26 (40.6%) juvenile, and 39 (48.4%) adult 
(>15 years of age). Twenty- four patients (34.3%) had a first degree 
relative with NPC disease. Six patients had cousins with NPC (8.6%) 
and 3 patients (4.3%) had higher- degree relatives with NPC.
The neurological symptoms observed (by the supervising cli-
nician) were: VSGP in 41 (56.9%) and VSSP in 48 patients (59.3%), 
gelastic cataplexy in 9 (12.7%), clumsiness or frequent falls in 52 
(72.2%), dysdiadochokinesis in 49 (70.0%), dysmetria in 50 (71.4%), 
intentional tremor in 29 (42.0%), and dysarthria and/or dysphagia 
in 63 (88.7%). Dyskinesia was observed in 26 cases (37.7%), dys-
tonia in 48 cases (67.6%), and acquired spasticity in 15 patients 
(21.1%). Delayed developmental milestones were observed in 13 
cases (18.3%). Fifteen patients (20.8%) demonstrated partial or 
generalized seizures, 9 patients (12.5%) showed myoclonus. Some 
62 patients (86.1%) demonstrated cognitive decline (children) or 
dementia (adults). Psychotic symptoms (hallucinations, delusions 
and/or thought disorder) were present in 16 patients (19.5%), 9 pa-
tients (12.5%) showed treatment- resistant psychiatric symptoms, 
whereas disruptive or aggressive behavior was observed in 24 pa-
tients (29.3%). Other psychiatric disorders were seen in 14 patients 
(19.7%). Patients’ medication included a number of central nervous 
system (CNS)- active agents: antiepileptics (9 patients, 12.5%), an-
tidepressants (11, 15.3%), nootropics (7, 9.7%), antipsychotics (10, 
13.9%), anti- Parkinsonian medication (including anticholinergics), 
and benzodiazepines (4, 5.6%). Three patients had hearing devices 
due to hearing loss. Acetyl- DL- leucine was administered in 21 pa-
tients (31.7%) for cerebellar ataxia [15]. One patient was treated 
with cyclodextrin, while ursodeoxycholic acid (UDCA) was adminis-
tered to a further patient (early- infantile case with profound visceral 
manifestation).
For a healthy control as a reference, 158 subjects from Germany 
and Slovakia with no presence of neurological, ophthalmological, 
or vestibular disease (55 F, age ± SD 41.7 ± 24.3 years) were also 
included to build up 95% confidence limits using the same testing 
paradigms.
The study was performed in accordance with the Helsinki II 
Declaration and approved by the ethics committee of the Ludwig 
Maximilian University Medical Faculty (addendum to project no. 
379– 12). The principal investigator (T.B.E.) initiated the study during 
her work in Munich, before she moved to Bern (see the Affiliation 
section). All participants or their legal guardians gave their informed 
consent prior to inclusion in the study.
Eye movement recordings and data analysis
For eye movement recordings, paradigms and all definitions of 
ocular- motor parameters, see Appendix S1.
Clinical evaluation
To assess disease severity, the modified Disability Rating Scale (mDRS) 
was applied [16]. Cerebellar function was evaluated by the Scale for the 
Assessment and Rating of Ataxia (SARA) [17] and the Spinocerebellar 
Ataxia Functional Index (SCAFI) [18]. To evaluate cognitive function, 
the Montreal Cognitive Assessment (MoCA) was used [19].
Statistical analysis
Statistical analysis and figure design were performed using SAS® 
Software version 9.3. Graph design was performed by GraphPad® 
Software version 5.0.3 (La Jolla, CA). Numerical variables in demographic 
and baseline characteristics were summarized by displaying the follow-
ing: n (actual sample size), mean, standard deviation, standard error, me-
dian, quartiles, 95% confidence intervals, and maximum and minimum. 
We reported the frequency and percentages (based on the non- missing 
sample size) of observed levels for all categorical measures. Parametric t- 
test was used to determine differences in the mean value between NPC 
patients and HC. Analysis of variance (ANOVA) was used to determine 
whether a mean value was statistically different among NPC subpopula-
tions (i.e., early- infantile, late- infantile, juvenile, and adults).
To assess which eye movement parameters could predict the 
severity of patients with NPC (i.e., correlation between video- 
oculographic impairment and disability scale), we used them as 
covariates in the univariable linear regression analysis. To study 
whether clinical parameters played a significant role in such correla-
tions, we ran multivariable regression analysis with a stepwise and 
forward selection method. In linear regression models, R2 of the lin-
ear regression line including controls are indicated.
We performed an observed case analysis, with all summary and 
percentages calculated relative to the number of patients with available 
ocular- motor data. In the resulting statistics, the denominators for anal-
ysis were the numbers of patients with the corresponding data. Patients 
who were not physically capable of performing the particular score tasks, 




The mean mDRS score was 10.3 points (SD, 95% CIs of the mean 5.0, 
[9.4, 11.5]) (n = 69), the mean SARA score was 13.3 points (9.4, [10.9, 
15.6]) (n = 63). The mean MoCA (n = 31) was 16.7 points (7.4, [14– 19.4]).
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Saccades
For a normal subject as a reference, see Figure 1A. As illustrated 
in Figure 1B– E, we observed different patterns of saccadic impair-
ment in patients with NPC. These patterns comprised hypometric 
(B), staircase- pattern (C), ‘normal slow’ (D), and pursuit- like pattern 
(E) (extremely slow, but still movement generated) saccades. As a 
compensating strategy, patients generated blinks to a very signifi-
cant extent (F). Saccades with blinks were excluded from the analy-
sis. Clinically observed head movements were avoided during the 
examination by chinrest and active help of the examiner/caregiver 
(Appendix S1). The trajectory of saccades can be seen in phase- 
plane plots of velocity versus amplitude (Figure 2). For a reference, 
see normal subjects (2A and 2B). We observed velocity fluctuation, 
visible as “wiggles”, both in reflexive and self- paced vertical saccades 
(2C and 2E), but not in the horizontal ones (2D and 2F).
Reflexive vertical saccades
Sixty- one patients were able to perform vertical saccades (73.2%) 
of 10° amplitude and 58 patients generated saccades to 20° (±10° 
up and down from center of 0°). Mean peak velocity of saccades in 
response to stimulus of 20° was 63.5°/s (59.5, [47.9– 79.2]) in NPC 
patients and 403.1°/s (69.0, [392.0– 414.2°/s]) in HC (p < 0.001). 
Downward saccades yielded the peak velocity of 51°/s (68.9, 
[32.7– 69.3]), whilst upward saccades measured 78.8°/s (65.9, [60.8– 
96.8]) (for both: p < 0.001). For saccadic gain (saccadic amplitude/
stimulus amplitude), see section on “Vertical Saccades and Vertical 
Smooth Pursuit” below. The overall characteristics of vertical sac-
cades differed when compared with healthy controls at p < 0.001 
levels, except for the latency (p < 0.05).
Reflexive horizontal saccades
Peak velocity of horizontal saccades in response to 30° was 311.7°/s 
(103.4, [284.6– 338.9]) in patients with NPC and 481.7°/s (78.1, 
[468.8– 494.5]) in HC (p < 0.001) (for both 15° and 30° saccades). 
All other saccadic characteristics (amplitude, duration, and maximal 
duration) except latency showed a significant difference.
Self- paced vertical saccades
Peak velocity of upward self- paced saccades to 20° was 158.8°/s 
(106.2, [39.9, 322]) in NPC patients and 352.7°/s (85.4, [251– 459]) 
in HC (p < 0.001). Peak velocity of downward self- paced saccades 
reached 162.3°/s (146.7, [292.7– 106.2]) in NPC and 352.8°/s (86.4, 
[458.5– 236]) in the control group (p < 0.001). In contrast to reflex-
ive saccades, NPC patients showed a prolonged intersaccadic inter-
val of self- paced saccades (as an equivalent of latency in reflexive 
F I G U R E  1  Overview of saccadic phenotypes in a healthy control and in NPC patients: A continuum. Phenotypes of vertical downward 
saccades in NPC disease are depicted. Red indicates the vertical eye movement and blue the horizontal eye movement. Grey depicts the 
stimulus. Figure A shows a vertical downward saccade of a normal subject. Note the high peak velocity (steep line) trajectory without 
fluctuations, latency <250 ms, amplitude and precision without hypo- or hypermetria, and trajectory without curving. A common finding in 
NPC is saccadic hypometria (B) >20% of the whole saccade. If hypometria is very profound, so- called staircase saccades, seen also often in 
patients with atypical Parkinson syndromes, are generated (C). Also notice a prolonged latency (time from the stimulus onset to the initiation 
of the downward movement). Reduced velocity of vertical saccades is depicted in (D), with a downward saccadic palsy in E. Note that that 
there is still extremely slow, pursuit- like movement, and the actual saccade performance takes more than two seconds. One of the most 
remarkable strategies seen in NPC is blinking (F). This strategy is used to initiate saccades that are already impaired. In contrast, patients with 
parkinsonian disorders do not blink to compensate for saccadic palsy due to lid apraxia or blepharospasmus. Note the continuum of saccadic 
impairment with different saccadic phenotypes.
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saccades). For upward saccades, this was 2.5 s (1.4, [1.2– 2.6]) in NPC 
and 1.1 s (0.4, [0.8– 1.6]) in HC. Regarding the downward saccades, 
it was 3.5 s in NPC (5.0, [1.2– 2.6]) and 1.03 (0.6, [0.8– 1.9]) in HC 
(p < 0.001). Patients generated a total mean number of 10.6 (19, [2– 
27]) upward saccades and 8.1 (9.0, [1.0– 29.0]) downward saccades 
in 30 s, whereas controls generated 30.6 (8.3, [19– 41]) upwards and 
25.8 (8.7, [16– 38]) downwards, respectively (for all p < 0.001).
Self- paced horizontal saccades
Peak velocity of rightward self- paced saccades yielded 244.6°/s 
(138.6, [179.7– 309.5]) in NPC and 449.8°/s (97.2, [432.7– 466.8] 
in HC. To the left, peak velocity reached 240°/s (152.7, [168.5– 
311.5]) in NPC and 429.8°/s (112.3, [410.1– 449.1]) in HC. As ex-
pected, the intersaccadic interval was significantly prolonged in 
NPC. To the right, it yielded 2.1 s (1.4, [1.5– 2.8]) in NPC and 1.4 s 
(0.7, [1.2– 1.5]) in HC. To the left, the intersaccadic interval was 
1.8 s (1.1, [1.3– 2.4]) and 1.3 s (0.5, [1.2– 1.4]) (for both p <0.001). 
The absolute number of elicited saccades to the right generated 
in 30 s was 15.7 (8.6, [11.6– 19.7]) in NPC and 25.7 (8.7, [24.1– 
27.2]) in HC (p < 0.001). To the left, the absolute number was 
14.6 (8.6, [10.6– 18.6]) in NPC and 26.5 (67.3, [91.1– 114.8]) in HC 
(p < 0.001). In all the other saccadic parameters, there were sig-
nificant differences when compared to HC (p< 0.001, for ampli-
tude p < 0.002).
F I G U R E  2  Phase plane plot of vertical 
saccades in a normal subject and in 
a patient with Niemann- Pick type C. 
Phase- plane plots depicting the saccadic 
amplitude vs velocity. The origin of each 
saccade has been moved to zero and 
the velocity at each position along the 
saccade trajectory is shown. Since larger 
amplitude saccades typically generate 
faster velocities, this generates a family 
of curves in which the saccade amplitude 
can be seen at the endpoint position. Note 
also the velocity fluctuation of saccades 
(wiggles), as shown in the phase- plane 
plot. The velocity variation (“wiggles”) 
is higher in vertical reflexive (C) than 
in vertical self- paced (E) saccades. This 
illustrates the difference between the 
reflexive and self- paced saccades.
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Reflexive vs. self- paced saccades
We ascertained whether there was a significant difference between 
the two types of examined saccades in NPC. For vertical reflexive 
saccades, peak velocity was 63.5°/s (59.5, [47.9– 79.2]). In contrast, 
peak velocity of vertical self- paced saccades was 160.6°/s (126.5, 
[166– 214]) (p < 0.001) (for an example, see Figure 2C reflexive vs. 
2E self- paced). Interestingly, this was not true for horizontal sac-
cades. For reflexive saccades, mean peak velocity was 311.7°/s 
(103.4, [284.6– 338.9]). In the self- paced task, peak velocity reached 
242.3°/s (145.7, [174.1– 310.5]).
Smooth pursuit
Vertical velocity smooth pursuit gain in response to 0.2 Hz stimulus 
frequency was 0.544 (0.269, [0.467– 0.621] in NPC and 0.572 (0.2, 
[0.54– 0.604]) in HC (p = 0.435). However, vertical position smooth 
pursuit gain was 0.649 (0.33, [0.554– 0.744]) in NPC and 0.935 
(0.149, [0.91– 0.959]) in HC (p < 0.001). Horizontal velocity smooth 
pursuit gain in response to 0.2 Hz was 0.619 (0.207, [0.546– 0.693]) 
in NPC and 0.812 (0.192, [0.781, 0.843]) in HC (p < 0.001). Horizontal 
position smooth pursuit gain to 0.2 Hz stimulus frequency was 0.979 
(0.213, [0.897, 1.060]) in NPC.
Comparison of vertical saccades and vertical 
smooth pursuit
98.2% of patients generated vertical saccades (both up and down) 
that were below the 95% confidence intervals of the controls’ peak 
velocity. This was not the case for smooth pursuit generated in 
response to 0.2 Hz stimulation, where only 46.9% of patients had 
smooth pursuit gain lower than that of 95% of HC. Gain (eye move-
ment amplitude vs stimulus amplitude) of vertical saccades in NPC 
patients was 0.525 (0.282, [0.451– 0.599]) and lower than smooth 
pursuit gain 0.649 (0.330, [0.554– 0.744]) (p = 0.038), while this was 
not true for HC (vertical saccadic gain: 0.953, (0.112, [0.935– 0.971]) 
vs smooth pursuit gain 0.935, (0.149, [0.910– 0.959]; p = 0.234).
For a juvenile- onset patient with NPC, suffering VSSP without 
VSGP, see Video S1. Signed informed consent was obtained from 
the patient.
Gaze- Holding
No significant gaze- holding deficit was observed.
Oculomotor characteristics based on age of onset
Due to the low number of early- infantile and late- infantile cases (12 
</= of age, in total 12, results of 7 of them were analyzable), thus 
reducing the probability of ANOVA statistically significant results, 
these groups were excluded from this analysis.
The characteristics of 10° saccades did not differentiate based 
on age of onset. 20° saccades differed in terms of amplitude of both 
upward and downward saccades, respectively (p = 0.035; p = 0.022). 
There was a trend for significance of velocity of upward saccades 
(p = 0.057), and downward amplitude (p = 0.051). 20° mean vertical 
saccadic velocity (p = 0.022) and amplitude (p = 0.016) were signifi-
cantly different based on the studied groups. In response to both 
15° and 30° stimuli, leftward and rightward saccades did not vary 
between the studied groups.
Horizontal but not vertical smooth pursuit was lower in juvenile- 
onset, than in adult- onset cases (p < 0.01).
Univariate linear regression and further analysis
Ocular- motor parameters that showed significant relationships with 
disease- specific and ataxia scales and R2 values with the tendency 
to significance are summarized in Table S2. All relationships (video- 
oculographic parameters vs neurological scales) were plotted and 
outcomes with significant p values and higher R2 were evaluated for 
data dispersion and fit of the regression line.
Univariate linear regression analysis showed that duration 
of 10° saccades is strongly related to disease state (R2 = 0.68) 
(Figure 3A,B), particularly 10° downward saccades. 20º vertical 
down amplitude tracked with mDRS (R2 = 0.61) (Figure 3C). 20° 
vertical saccadic amplitude was a negative predictor to time of 
SCAFI 9- Hole- Peg- Test of the Dominant Hand (9HPTD) (R2 = 0.58) 
(Figure 3D), but also mDRS (R2 = 0.58). Peak velocity of vertical 
saccades was not useful in predicting disease severity (for up/down 
and 10°/20°, R2 < 0.2).
Peak velocity of 15° left horizontal saccades was significantly re-
lated to mDRS scale (R2 = 0.53) (Figure 3E), when combined with 15º 
horizontal left- right peak velocity (R2 = 0.46) (Figure 3F). Horizontal 
saccadic combined (left- right) PV and SARA score yielded R2 of 0.38 
(30° saccades) and R2 of 0.37 (15° saccades) (Figure 3G). SCAFI do-
main 9HPTD and peak velocity of 15° left- right saccades yielded R2 
of 0.35 (Figure 3H). Latency of 15° rightward saccades tracked with 
SCAFI 9HPTD Score (R2 = 0.56).
Position smooth pursuit gain to 0.2 Hz stimulation was related 
to both mDRS and SARA scores to a modest extent (R2 = 0.32 vs 
R2 = 0.31) (Figure 3I,J). Gaze- holding did not reflect disease severity.
Miglustat treatment was used as a covariate in the multivariate 
regression analysis; however, the assessment of its role was ham-
pered by the patient- to- patient variability and restricted sample 
sizes.
In patients treated >1 year, peak velocity of 10º upward 
saccades (p = 0.046) was significantly lower, probably due to 
NPC disease duration, de facto suffering an advanced disease. 
Regarding horizontal saccades, we found a lower peak velocity to 
15º stimulus (right p = 0.048; left p = 0.031) and to 30º stimulus 
(p = 0.004).
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F I G U R E  3  Saccadic and smooth pursuit parameters and their relationships to neurological scores.
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DISCUSSION
Ocular- motor function in NPC disease has not previously been ana-
lyzed in a large cohort of patients due to its rarity and underdiag-
nosis. We systematically examined reflexive and self- paced vertical 
and horizontal saccades, smooth pursuit and gaze- holding as func-
tional outputs of the brainstem, cerebellum and cortical centers. The 
major findings of this study are as follows:
First, quantitative measurements of eye movements showed that 
VSSP, not VSGP, is the cardinal symptom of NPC disease. Second, 
contrary to what is commonly reported, downward and upward 
saccades are impaired to a similar extent. Third, reflexive vertical 
saccades were more impaired and slower than self- paced ones. In 
contrast, the velocity of horizontal self- paced saccades was lower 
than their reflexive counterparts. Fourth, horizontal saccadic peak 
velocity and latency, amplitude and duration of vertical saccades, 
and gain of positional smooth pursuit were the most relevant vari-
ables reflecting clinical state. Fifth, ocular- motor status was de-
pendent on age of onset and disease duration. Sixth, we observed 
patient- specific saccadic phenotypes, but due to the compound het-
erozygosity, genotype- ocular- motor phenotype correlation was not 
possible. Of note, we noticed patients apply blinking, and head and 
upper body movements to initiate and accelerate the saccades and 
to overcome gaze difficulty [20,21]. Clinicians should actively search 
for these clues.
Vertical Supranuclear Saccadic vs. Gaze Palsy
Prior to this analysis, VSGP but not VSSP has been highlighted as 
a cardinal symptom of NPC; this however fails to acknowledge the 
specific ocular- motor impairment characteristic of the disease. The 
terminology has not been used clearly, potentially contributing to 
the lack of descriptive accuracy of the saccadic eye movements de-
fect in patients. In clinical practice, the ocular- motor examination is 
often restricted to following the slowly moving target when looking 
for gaze limitations, thus examining smooth pursuit, whereby slow 
vertical saccades may be overlooked. Thus, a thorough ocular- motor 
examination of both saccades and smooth pursuit movements will 
ensure that VSSP is not missed. Whilst VSGP has been shown to be 
present in 70% of patients from an international patient registry [22], 
we demonstrate here that VSSP is present in 98.2% of patients, but 
VSGP in only 46.9% (Video S1). VSGP is present in advanced stages 
of ocular- motor impairment, when the disease is already diagnosed.
Vertical saccades are often accompanied by the “around the 
house” sign (curved saccade trajectory when plotted in X- Y space) 
(Video S1), typical of saccadic palsy in one plane [23], also seen in 
other lysosomal storage diseases (LSDs), like Gaucher disease type 
3 [24]. Clinicians should be trained to recognize and differentiate 
impairments of the saccadic system from impairments of smooth 
pursuit, and understand the possibility of combined deficits. To 
emphasize the important distinction between VSSP and VSGP, we 
suggest revising the current terminology with regards to saccadic 
vs. gaze palsy also in other LSDs and neurodegenerative diseases 
like progressive supranuclear palsy (PSP) [25,26]. Saccadic palsy is 
the initial symptom due to the selective vulnerability of the saccadic 
neurons, probably due to their high metabolic properties, but the 
underlying pathophysiology is not known.
Vertical saccadic patterns
We observed different saccadic patterns that were patient- specific, 
such as slow saccades, and extremely slow, “pursuit- like” saccades, 
where the saccade resembled a pursuit movement. Saccade- 
generating burst neurons are inhibited by omnipause neurons, 
except during saccadic performance and blinks [27,28]. Due to tran-
sient velocity fluctuations during the saccade, suggestive of omni-
pause neuron dysfunction, we argue the movement was generated 
by burst neurons in riMLF, rather than the pursuit system. Patients 
generated hypometric saccades with either one large corrective 
saccade (>20% of amplitude of first saccade) or so- called staircase 
pattern saccades. The number of saccadic steps varied from 2 to 
10. Hypometric saccades are common for atypical Parkinson syn-
dromes, such as PSP, the main differential diagnosis for the adult 
form of NPC, supporting the association between NPC and other 
neurodegenerative disorders [25,26,28].
VSSP/VSGP compensating strategies
Although not the main objective of this study, we demonstrate that 
observable compensation strategies patients utilize to overcome 
ocular- motor deficits can assist in establishing the diagnosis of NPC. 
To elicit and speed- up the saccades, patients blink to silence omni-
pause neurons that inhibit burst excitatory neurons. To overcome 
palsy of gaze, patients produce high- amplitude head movements 
or even upper body movements. This can often be seen in children 
[20,21]. We strongly encourage clinicians to look for these move-
ment clues that compensate for subclinical ocular- motor impair-
ment, which should prompt thorough ocular- motor and neurological 
examinations.
Reflexive vs. Self- paced saccades
Peak velocity of vertical, but not horizontal, self- paced and reflexive 
saccades in response to the same amplitude significantly differed. 
This is surprising, since burst neurons for all saccades have a com-
mon supranuclear center, namely riMLF for vertical and pontine 
paramedian reticular formation (PPRF) for horizontal saccades [10]. 
The firing rate of the excitatory burst neurons is linearly aligned with 
the saccadic velocity [29]. The reason self- paced saccades, a marker 
for degenerative and traumatic brain disorder [30– 32], reach higher 
peak velocity is unclear, considering impaired cognition and process-
ing speed in NPC.
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There may be different involvement of supra- riMLF pathways, 
namely frontal eye field for self- paced and parietal eye field for re-
flexive saccades [3,33]. The characteristics of both self- paced and 
reflexive saccades were pathological when compared to the healthy 
population. We speculate that the rapidly changing visual stimulus 
for highly disturbed vertical reflexive saccades might represent a 
relevant stressor that compromises the performance. Horizontal 
saccades also showed a remarkable decrease of peak velocity and 
prolonged duration, demonstrating the functional impairment of the 
PPRF in the pons, but they are affected to a lesser extent.
As expected, latency in vertical reflexive saccades was normal, 
but the intersaccadic interval was greatly prolonged. This supports 
the progressive frontal impairment in NPC.
Upward vs. Downward saccades
In contrast to the commonly perceived discrepancy between down-
ward and upward saccades due to the mono- (ipsi- ) and bilateral 
supranuclear innervation of oculomotor nuclei by the riMLF, both 
downward and upward saccades showed similar characteristics, in-
cluding peak velocities. This might be because the bilateral upward 
innervation is counteracted by gravity. In neurodegeneration, the 
same degree of functional impairment results in both directions. 
Less frequent upward eye movements might lead to a worse up-
ward motor function, when compared with common downward eye 
movements, due to a training- effect.
Use as biomarkers
Even though vertical saccades show similar peak velocities in both di-
rections, the duration of downward saccades correlates with the state 
of disease more than the duration of upward ones. Our results suggest 
that position, not velocity smooth pursuit profile, can be established 
as a surrogate parameter. Interestingly, this is more the case for verti-
cal, not horizontal smooth pursuit. The characteristics of self- paced 
saccades might be a useful biomarker, especially total count and peak 
velocity. Further ocular- motor studies using this task are needed. In 
terms of important covariants, disease duration affected the ocular- 
motor systems to a considerable extent, as expected. Additionally, 
ocular- motor function in NPC1 heterozygotes (one mutation carriers) 
is similar to patients with manifest disease (with two underlying muta-
tions), replicating the neurodegenerative pattern [34]. Thus, the iden-
tified ocular- motor parameters can be used in NPC1 heterozygotes to 
screen for neurological impairments. Once created, the parameters 
may be used to evaluate disease progression treatment effects.
Limitations
The primary limitation of this study was the disease complexity 
and level of the patients’ disability, with incomplete data in some 
patients. We admit that not including the most severely impaired 
patients might represent a selection bias. However, these patients 
have often already a total gaze palsy, including horizontal eye move-
ments so that the ceiling effect of the video- oculographic testing 
would be probably reached. Many patients utilized dopaminergic, 
anti- epileptic and anti- psychotic medication. Medication effects on 
ocular- motor function are expected, but due to a number of diverse 
medications, we were not able to study their functional relevance.
Dividing the patient population into groups led to smaller sample 
sizes, thus reducing the power of the study. The cross- sectional and 
uncontrolled design of the study is a limitation in this progressive 
neurodegenerative disease.
CONCLUSIONS
The cardinal ocular- motor sign of NPC disease is VSSP. All patients 
with VSGP demonstrate a saccadic impairment, but not all patients 
with VSSP show gaze palsy.
Parameters that could serve as surrogate endpoints are hori-
zontal saccadic characteristics, with position, vertical smooth pur-
suit gain and vertical saccadic duration, and amplitude as secondary 
endpoints. VSSP can help clinicians diagnose NPC in its initial stages. 
Early diagnosis is essential so that disease- modifying treatment, 
which slows neurologic progression and prolongs life- expectancy, 
can be initiated before the window of therapeutic opportunity is 
lost.
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